myTomorrows, a global health technology firm, has announced its partnership with Pancreatic Cancer Europe to streamline access to clinical trial information. This collaboration aims to help patients, caregivers, and healthcare professionals make informed decisions regarding pre-approval treatments. By utilizing myTomorrows’ extensive database, Pancreatic Cancer Europe looks to provide up-to-date and accessible treatment options to those battling pancreatic cancer.
Pancreatic cancer remains a daunting health challenge, being the fourth leading cause of cancer-related deaths globally. The disease is characterized by late diagnosis, treatment resistance, and limited treatment options, leading to a grim life expectancy of just 6-12 months post-diagnosis and a five-year survival rate of only 10%. The critical need for accurate and comprehensive information on treatment options, particularly clinical trials, has been emphasized by various health experts.
Enhanced Access to Clinical Trials
The new partnership will introduce a clinical trial search tool on the Pancreatic Cancer Europe website, significantly easing the process of finding relevant treatment options globally. myTomorrows’ expert patient navigators will assist in demystifying the complexities of clinical trials, providing continuous support to patients and families. This tool aims to accelerate and simplify the search for suitable clinical trials for pancreatic cancer patients.
Pancreatic Cancer Europe hopes this collaboration will enable patients to take a proactive and informed approach to their treatment. This move aligns with their ongoing efforts to raise awareness and promote advancements in pancreatic cancer treatments. The partnership also aims to enhance communication between patients, caregivers, and healthcare professionals, facilitating better decision-making.
Statements from Leaders
“We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to raise awareness of pancreatic cancer, promote advancements in treatments, and empower European member organisations to better address the relevant issues regarding the disease,” said Dr. Michel van Harten, CEO of myTomorrows. “Collaborating with leading patient advocacy groups like PCE helps us extend our reach to more patients in need and empower them to navigate their treatment journeys with more confidence and knowledge, while enabling pharmaceutical companies to expand access throughout the drug development cycle.”
“This new partnership is an important step in the persistent fight against pancreatic cancer,” said Prof. Alfredo Carrato, Chair of Pancreatic Cancer Europe. “The innovative myTomorrows platform will support patients suffering from pancreatic cancer, their caregivers and their treating physicians by significantly easing the process of accessing and navigating clinical trials, another opportunity for them, enabling a more informed and proactive approach to treatment of this devastating disease.”
The new collaboration between myTomorrows and Pancreatic Cancer Europe represents a significant step forward in the fight against pancreatic cancer. By making clinical trial information more accessible and understandable, this partnership could potentially improve survival rates and the quality of life for patients. Healthcare professionals will also benefit from having a more streamlined process for identifying suitable clinical trials, ultimately leading to better patient outcomes.
